Yin Kanhua, Willie-Permor Daniel, Zarrintan Sina, Dakour-Aridi Hanaa, Ramirez Joel L, Iannuzzi James C, Naazie Isaac, Malas Mahmoud B
Department of Surgery, Washington University School of Medicine, St Louis, MO.
Division of Vascular and Endovascular Surgery, University of California, San Diego, La Jolla, CA.
J Vasc Surg. 2023 Feb;77(2):357-365.e1. doi: 10.1016/j.jvs.2022.08.037. Epub 2022 Sep 8.
It is uncertain whether preoperative anemia is independently associated with thoracic endovascular aortic repair (TEVAR) outcomes. Using a national vascular surgery database, we evaluated the associations between preoperative anemia and 30-day mortality, postoperative complications, and 1-year survival for patients undergoing TEVAR.
We retrospectively analyzed all patients in the Vascular Quality Initiative who had undergone TEVAR for aortic dissection, aortic aneurysm, penetrating aortic ulcer, hematoma, or thrombus between January 2011 and December 2019. We excluded patients with a ruptured aneurysm, traumatic dissection, emergent repair, treated aorta distal to zone 5, polycythemia, transfusion of >4 U of packed red blood cells intraoperatively or postoperatively, and missing data on hemoglobin level or surgical indications. The final study cohort was dichotomized into two groups: normal/mild anemia (women, ≥10 g/dL; men, ≥12 g/dL) and moderate/severe anemia (women, <10 g/dL; male, <12 g/dL). Propensity scores by stratification were used to control for confounding in the analysis of the association between the outcomes of 30-day mortality, postoperative complications, and 1-year survival and a binary indicator variable of moderate/severe anemia vs normal/mild anemia. Kaplan-Meier analysis and log-rank tests were used to compare the 1-year survival between the two groups. A Cox regression model was fitted to assess the associations between anemia and survival outcomes.
A total of 3391 patients were analyzed, 958 (28.3%) of whom had had moderate/severe anemia. After adjustment for multiple clinical factors using propensity score stratification, moderate/severe anemia was associated with a 141% increased odds of 30-day mortality (adjusted odds ratio [aOR], 2.41; 95% confidence interval [CI], 1.15-5.05; P = .019), 58% increased odds of any in-hospital complication (aOR, 1.58; 95% CI, 1.17-2.13; P = .003), 281% increased odds of intraoperative transfusion (aOR, 3.81; 95% CI, 2.68-5.53; P < .001). In addition, moderate/severe anemia was associated with significantly worse survival within the first year after TEVAR (log-rank P < .001; 1-year survival rate using Kaplan-Meier estimates, 86.4% ± 1.3% standard error vs 92.5% ± 0.6% standard error) and with an increased risk of mortality in the first postoperative year (adjusted hazard ratio, 1.81; 95% CI, 1.16-2.82; P = .009).
We found that moderate or severe anemia is associated with significantly increased odds of mortality, postoperative complications, and worse 1-year survival after TEVAR. Future studies are needed to evaluate the effect of anemia correction on the outcomes of TEVAR.
术前贫血是否与胸主动脉腔内修复术(TEVAR)的预后独立相关尚不确定。我们利用一个全国性血管外科数据库,评估了接受TEVAR治疗的患者术前贫血与30天死亡率、术后并发症及1年生存率之间的关联。
我们回顾性分析了2011年1月至2019年12月期间在血管质量改进计划中因主动脉夹层、主动脉瘤、穿透性主动脉溃疡、血肿或血栓而接受TEVAR治疗的所有患者。我们排除了动脉瘤破裂、创伤性夹层、急诊修复、5区以下主动脉治疗、红细胞增多症、术中或术后输注超过4单位浓缩红细胞以及血红蛋白水平或手术指征数据缺失的患者。最终研究队列分为两组:正常/轻度贫血(女性,≥10 g/dL;男性,≥12 g/dL)和中度/重度贫血(女性,<10 g/dL;男性,<12 g/dL)。在分析30天死亡率、术后并发症和1年生存率的结果与中度/重度贫血与正常/轻度贫血的二元指示变量之间的关联时,采用分层倾向评分来控制混杂因素。采用Kaplan-Meier分析和对数秩检验比较两组的1年生存率。拟合Cox回归模型以评估贫血与生存结果之间的关联。
共分析了3391例患者,其中958例(28.3%)患有中度/重度贫血。使用倾向评分分层对多个临床因素进行调整后,中度/重度贫血与30天死亡率增加141%相关(调整后的优势比[aOR],2.41;95%置信区间[CI],1.15 - 5.05;P = 0.019),任何院内并发症的几率增加58%(aOR = 1.58;95% CI,1.17 - 2.13;P = 0.003),术中输血几率增加281%(aOR = 3.81;95% CI,2.68 - 5.53;P < 0.001)。此外,中度/重度贫血与TEVAR术后第一年内显著更差的生存率相关(对数秩P < 0.001;使用Kaplan-Meier估计的1年生存率,标准误为86.4% ± 1.3% 与92.5% ± 0.6%),且与术后第一年死亡风险增加相关(调整后的风险比,1.81;95% CI,1.16 - 2.82;P = 0.009)。
我们发现中度或重度贫血与TEVAR术后死亡率显著增加、术后并发症及更差的1年生存率相关。未来需要开展研究以评估纠正贫血对TEVAR预后的影响。